Dyax Corp. DYAX today announced dosing of the first subject in a
Phase 1 clinical study evaluating the safety and tolerability of single
subcutaneous administration of DX-2930, its fully human monoclonal antibody
inhibitor of plasma kallikrein. Dyax, a biopharmaceutical company focused on
hereditary angioedema (HAE) and other plasma kallikrein-mediated disorders, is
developing DX-2930 as a subcutaneous injection for prevention of HAE attacks.
DX-2930 was discovered using Dyax's proprietary phage display technology
platform.
“There is significant need for a highly effective, safe and well tolerated
prophylactic agent to treat HAE,” said Burt Adelman M.D., Executive Vice
President and Chief Medical Officer at Dyax. “DX-2930 is a highly potent,
long-acting, fully human monoclonal antibody that binds specifically to active
plasma kallikrein. We look forward to completing this study and moving forward
rapidly with this important clinical program.”
This Phase 1, single-center, randomized, double-blind, placebo-controlled
study is designed to assess the safety and tolerability and to characterize
the pharmacokinetics (PK) of single, subcutaneous administrations of DX-2930
in healthy subjects. Approximately 32 subjects will be enrolled into four
ascending dose cohorts (n=8 per cohort) of DX-2930 or placebo. The study will
be conducted at the clinical trials unit of Vince & Associates Clinical
Research, a recognized “Center of Research Excellence”, located in Overland
Park, Kansas.
“The successful dosing of the first subject in this Phase 1 clinical study is
an important milestone for the DX-2930 development program,” said Gustav
Christensen, President and CEO of Dyax. “We believe our knowledge of the
plasma kallikrein pathway provides us with unique insight and a significant
advantage in developing and commercializing this product candidate.”
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in